Acorda Therapeutics (NASDAQ:ACOR)‘s stock had its “hold” rating reissued by stock analysts at JPMorgan Chase & Co. in a report released on Friday.
A number of other research firms have also weighed in on ACOR. BidaskClub lowered shares of Acorda Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, June 19th. TheStreet upgraded shares of Acorda Therapeutics from a “d+” rating to a “c-” rating in a research note on Tuesday, June 19th. ValuEngine lowered shares of Acorda Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 18th. Zacks Investment Research upgraded shares of Acorda Therapeutics from a “hold” rating to a “buy” rating and set a $33.00 price target for the company in a research report on Tuesday, July 3rd. Finally, Cantor Fitzgerald began coverage on shares of Acorda Therapeutics in a research report on Thursday, August 23rd. They set a “neutral” rating and a $32.00 price target for the company. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and four have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $24.17.
Acorda Therapeutics stock traded up $0.13 during mid-day trading on Friday, reaching $17.68. The company’s stock had a trading volume of 587,654 shares, compared to its average volume of 651,744. Acorda Therapeutics has a 12-month low of $15.60 and a 12-month high of $36.35. The firm has a market capitalization of $933.06 million, a price-to-earnings ratio of 17.00 and a beta of 1.52. The company has a current ratio of 4.09, a quick ratio of 3.92 and a debt-to-equity ratio of 0.56.
Acorda Therapeutics (NASDAQ:ACOR) last released its quarterly earnings data on Thursday, August 2nd. The biopharmaceutical company reported $1.40 earnings per share for the quarter, beating analysts’ consensus estimates of $0.50 by $0.90. Acorda Therapeutics had a negative net margin of 26.87% and a positive return on equity of 8.19%. The business had revenue of $153.30 million during the quarter, compared to analyst estimates of $138.63 million. During the same period in the previous year, the business earned $0.29 EPS. Acorda Therapeutics’s revenue was up 10.0% compared to the same quarter last year.
In other news, insider Burkhard Blank sold 6,250 shares of Acorda Therapeutics stock in a transaction on Wednesday, August 1st. The shares were sold at an average price of $24.69, for a total transaction of $154,312.50. Following the completion of the sale, the insider now directly owns 34,400 shares of the company’s stock, valued at approximately $849,336. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Scopia Capital Management Lp sold 153,858 shares of Acorda Therapeutics stock in a transaction on Tuesday, October 9th. The stock was sold at an average price of $17.28, for a total transaction of $2,658,666.24. The disclosure for this sale can be found here. Insiders have sold a total of 607,096 shares of company stock valued at $14,185,528 over the last 90 days. Company insiders own 7.80% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. FMR LLC lifted its holdings in shares of Acorda Therapeutics by 5.2% during the 2nd quarter. FMR LLC now owns 6,998,913 shares of the biopharmaceutical company’s stock worth $137,879,000 after acquiring an additional 348,895 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Acorda Therapeutics by 4.1% during the 2nd quarter. Vanguard Group Inc. now owns 4,308,160 shares of the biopharmaceutical company’s stock worth $84,871,000 after acquiring an additional 168,571 shares during the last quarter. Scopia Capital Management LP bought a new stake in shares of Acorda Therapeutics during the 3rd quarter worth $87,780,000. Eagle Asset Management lifted its stake in Acorda Therapeutics by 64.3% in the third quarter. Eagle Asset Management now owns 3,893,968 shares of the biopharmaceutical company’s stock worth $103,228,000 after purchasing an additional 1,523,974 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in Acorda Therapeutics by 5.7% in the first quarter. Dimensional Fund Advisors LP now owns 3,121,775 shares of the biopharmaceutical company’s stock worth $73,830,000 after purchasing an additional 167,084 shares during the last quarter.
About Acorda Therapeutics
Acorda Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia.
Recommended Story: Inflation
Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.